Deepak Chemtex sets Sept 21 AGM; e-voting opens Sept 18
- Deepak Chemtex holds AGM on Sept 21, 2026, via VC/OAVM
- Remote e-voting window opens Sept 18 and closes Sept 20
- FY26 PAT fell 35% to ₹659.25 lakh; revenue was ₹5,349.61 lakh
- Shareholders to reappoint MD Saurabh Deepak Arora and WTD Trishla Baid Arora
- Omnibus approval sought for ₹50 crore related-party transactions with subsidiary

*this image is generated using AI for illustrative purposes only.
Deepak Chemtex Limited has scheduled its 29th Annual General Meeting (AGM) for Monday, September 21, 2026, at 12:30 pm via Video Conferencing or Other Audio-Visual Means (OAVM). The company announced that remote e-voting will commence on Friday, September 18, and end on Sunday, September 20, 2026.
The Board of Directors approved the Directors' Report and Management Discussion and Analysis for FY26 during a meeting on August 24, 2026. The notice of the AGM along with the annual report for FY25-26 was dispatched electronically on Thursday, August 27, 2026. Saurabh Deepak Arora, Managing Director, signed the communication dated August 27, 2026.
Financial Performance FY26
As per the explanatory statement, Deepak Chemtex reported the following financial results for FY26:
| Metric | Amount (₹ in lakhs) |
|---|---|
| Revenue from Operations | 5,349.61 |
| Profit After Tax | 659.25 |
The subsidiary, DCPL Speciality Chemicals Private Limited, reported a turnover of ₹2,508.95 lakh and a profit after tax of ₹222.13 lakh for FY26.
Key Agenda Items
The AGM will transact ordinary business, including the adoption of audited standalone and consolidated financial statements for FY26. Special business includes the reappointment of key directors and approval of material related-party transactions.
Director Reappointments
Shareholders will vote on the following special resolutions:
- Reappointment of Mr. Saurabh Deepak Arora as Chairman and Managing Director for three years, effective July 28, 2026.
- Reappointment of Mrs. Trishla Baid Arora as Whole-time Director for three years, effective July 28, 2026.
Both directors are eligible for remuneration not exceeding ₹10 lakh per month, subject to board discretion. In case of inadequate profits, they will be entitled to minimum remuneration under Schedule V of the Companies Act, 2013.
Related-Party Transactions
The company seeks shareholder approval for material related-party transactions with its subsidiary, DCPL Speciality Chemicals Private Limited (DCPL). Deepak Chemtex holds a 90% stake in DCPL.
The proposed omnibus approval covers sales and purchases of goods, including Florosine Lumps, Manganese Di Oxide Powder, and Ethyl Benzyl Aniline Sulphonic Acid. The aggregate value of these transactions is capped at ₹50 crore until the next AGM.
E-Voting Details
In compliance with Section 108 of the Companies Act, 2013 and Regulation 44 of the SEBI Listing Regulations, the company has engaged NSDL for providing remote e-voting facilities. Members participating through VC/OAVM shall be reckoned for the purpose of quorum under Section 103 of the Companies Act, 2013.
Key dates for e-voting are as follows:
- Cut-off Date for e-voting: Monday, September 14, 2026
- Commencement of remote e-Voting: Friday, September 18, 2026, at 9:00 am (IST)
- End of remote e-Voting: Sunday, September 20, 2026, at 5:00 pm (IST)
Members holding shares in dematerialized mode, physical mode, or who have not registered their email addresses may cast their votes remotely or during the AGM. Ms. Nikita Keda, Proprietor of N K M & Associates, has been appointed as the Scrutinizer to oversee the voting process.
Historical Stock Returns for Deepak Chemtex
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -3.79% | 0.0% | -1.24% | -8.22% | -38.00% | 0.0% |
How might the reappointment of key directors and the approval of ₹50 crore in related-party transactions influence investor confidence and future corporate governance perceptions?
Given the subsidiary DCPL's significant contribution to consolidated profits, what strategic initiatives are planned to sustain or grow its margin performance in FY27?
Will the approved remuneration structure for the Managing Director and Whole-time Director align with industry benchmarks for similar-sized specialty chemical firms?

































